Lynparza 150 MG tablet UU 120S
Ended Awarded
- Contract number
- SPE2DB26FAAE7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,135
Award facts
- Contract value 100% obligated
- $21,135.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $21,135.22 delivery order to AmerisourceBergen Drug Corp for supply of LYNPARZA (olaparib) 150 mg tablets in quantities of 120 units. This is a firm fixed price, competitively awarded order with no set-aside designation, due for completion by November 10, 2025. The award was issued on October 20, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, one of the nation's major pharmaceutical distributors and healthcare solutions providers, has demonstrated significant capability in fulfilling federal medical procurement requirements through its extensive portfolio of competitive awards with the Defense Logistics Agency. The company supplies a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. LYNPARZA is a targeted cancer therapy used primarily for the treatment of certain ovarian and breast cancers, reflecting the military healthcare system's need for advanced oncology medications to support service members and their families.
Quick answers
Who was awarded contract SPE2DB26FAAE7?
SPE2DB26FAAE7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FAAE7 worth?
The government has obligated $21,135 on SPE2DB26FAAE7.
Is contract SPE2DB26FAAE7 an order under another contract?
Yes. SPE2DB26FAAE7 is a delivery order under SPE2DB22D3016, an indefinite delivery contract.
Was contract SPE2DB26FAAE7 competed?
The extent of competition for SPE2DB26FAAE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award